Global Markets For Peripheral Endovascular And Vascular Closure Devices To Show Impressive Growth Through 2019
Percutaneous transluminal angioplasty to lead the way with double-digit annual growth, driving expansion in U.S. and international markets
HUNTINGTON BEACH, Calif., Jan. 8, 2015 /PRNewswire/ -- According to a new analysis by Life Science Intelligence (LSI), Global Markets for Peripheral Endovascular and Vascular Closure Devices in 2015, robust market growth is expected for peripheral endovascular devices in U.S. and international regions.
Endovascular therapies have seen rising adoption due to new product introductions, the increasing prevalence of peripheral artery disease, developing healthcare systems in emerging markets, and the desire to utilize minimally invasive interventions. However, clinical challenges and suboptimal long-term outcomes for many patients, primarily from restenosis, have motivated caregivers and manufacturers to explore new devices and techniques.
Efforts to improve outcomes have led to a variety of atherectomy technologies; devices tailored for crossing occluded lesions; stents with specialized or drug-eluting features; embolic protection devices; and, most recently, drug-coated balloons (DCBs). DCBs are expected to spur market growth and account for a rapidly increasing share of the balloon catheters used during percutaneous transluminal angioplasty. While multiple DCBs are available in Europe, only one is currently available in the U.S.—C.R. Bard's Lutonix 035 Drug Coated Balloon PTA Catheter, approved by the FDA in October 2014—although additional product approvals are expected in the coming years.
Technological innovations, growing clinical experience, and shifting healthcare dynamics are expected to profoundly shape the market for peripheral endovascular devices through 2019, as discussed in LSI's timely new analysis. The report covers global markets for atherectomy products, balloon catheters, chronic total occlusion devices, embolic protection devices, peripheral vascular stents, and vascular closure devices. Industry competitors include Aachen Resonance, Abbott Vascular, AccessClosure, AngioScore, Angioslide, Avinger, B. Braun, Bayer Interventional, Baylis Medical, Biotronik, Boston Scientific, C.R. Bard, Cardiovascular Systems, Cook Medical, Covidien, Eurocor, Johnson & Johnson, Medtronic, Minvasys, Natec Medical, Spectranetics, St. Jude Medical, Straub Medical, Teleflex Medical, Terumo Interventional Systems, Trireme Medical, Vascular Solutions, Volcano, and W.L. Gore & Associates.
Additional details on this new study can be found here: Global Markets for Peripheral Endovascular and Vascular Closure Devices in 2015
About Life Science Intelligence
Life Science Intelligence (LSI) delivers high-quality global market intelligence products to medical technology executives, entrepreneurs, and investors.
Contact
Scott Pantel
Life Science Intelligence
714 847 3540
[email protected]
www.lifescienceintelligence.com
SOURCE Life Science Intelligence
Share this article